Investor Presentation First Nine Months of 2023

16 Investor presentation First nine months of 2023 Financial outlook for 2023 Sales growth - at CER Expectations 2 November 2023 32% to 38% Expectations 10 August 2023 27% to 33% Sales growth - reported Operating profit growth - at CER Operating profit growth - reported Around 4 percentage points lower 40% to 46% Around 7 percentage points lower Around 6 percentage points lower 31% to 37% Around 9 percentage points lower Financial items (net) Effective tax rate Free cash flow Gain of around DKK 1.6 billion 19% to 21% DKK 65 to 73 billion Gain of around DKK 2.8 billion 19% to 21% DKK 64 to 72 billion Novo NordiskⓇ The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 26 October 2023 CER: Constant exchange rates Note: Changes since last highlighted in bold

View entire presentation